2021/07/19 MVC COVID-19 Vaccine Obtains Taiwan EUA Approval

TAIPEI, TAIWAN --July 19th, 2021. Medigen Vaccine Biologics Corp (MVC) obtains Taiwan EUA approval due to MVC's COVID-19 vaccine has fulfilled following EUA standards set by Taiwan's regulatory agencies:

1.For the GMT of MVC-COV1901, the lower bound of 95% confidence interval (CI) is 3.4 times the GMT of AstraZeneca. (Set criteria: 0.67 times the GMT of AstraZeneca.)  

2.For the sero-response rate of MVC-COV1901, the lower bound of 95% CI achieved 95.5%, which far exceeded the set threshold of 50%.  
MVC COVID-19 vaccine is indicated for adults over 20 years old and vaccinated in two doses 28 days apart for prevention of COVID-19. The Advisory Committee recommended that MVC should submit safety monitoring report monthly during the declared EUA period and should submit a vaccine effectiveness report within one year after obtaining EUA approval.

We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.